These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34630050)

  • 1. Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer's Disease Patients.
    Cimenser A; Hempel E; Travers T; Strozewski N; Martin K; Malchano Z; Hajós M
    Front Syst Neurosci; 2021; 15():746859. PubMed ID: 34630050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer's disease.
    Hajós M; Boasso A; Hempel E; Shpokayte M; Konisky A; Seshagiri CV; Fomenko V; Kwan K; Nicodemus-Johnson J; Hendrix S; Vaughan B; Kern R; Megerian JT; Malchano Z
    Front Neurol; 2024; 15():1343588. PubMed ID: 38515445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Fast Gamma Magnetic Stimulation Over the Left Prefrontal Dorsolateral Cortex for the Treatment of MCI and Mild Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled, Pilot Study.
    Mimenza-Alvarado AJ; Aguilar-Navarro SG; Martinez-Carrillo FM; Ríos-Ponce AE; Villafuerte G
    Front Neurol; 2021; 12():729872. PubMed ID: 34566873
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased long distance event-related gamma band connectivity in Alzheimer's disease.
    Başar E; Femir B; Emek-Savaş DD; Güntekin B; Yener GG
    Neuroimage Clin; 2017; 14():580-590. PubMed ID: 28367402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered Cortical and Hippocampal Excitability in TgF344-AD Rats Modeling Alzheimer's Disease Pathology.
    Stoiljkovic M; Kelley C; Stutz B; Horvath TL; Hajós M
    Cereb Cortex; 2019 Jun; 29(6):2716-2727. PubMed ID: 29920597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer's Disease.
    Da X; Hempel E; Ou Y; Rowe OE; Malchano Z; Hajós M; Kern R; Megerian JT; Cimenser A
    J Alzheimers Dis; 2024; 97(1):359-372. PubMed ID: 38073386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-sectional and longitudinal assessments of function in prodromal-to-mild Alzheimer's disease: A comparison of the ADCS-ADL and A-IADL-Q scales.
    Teng E; Li Y; Manser PT; Pickthorn K; Butcher BD; Blendstrup M; Randolph C; Sikkes SAM
    Alzheimers Dement (Amst); 2023; 15(2):e12452. PubMed ID: 37325545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies.
    Chan D; Suk HJ; Jackson BL; Milman NP; Stark D; Klerman EB; Kitchener E; Fernandez Avalos VS; de Weck G; Banerjee A; Beach SD; Blanchard J; Stearns C; Boes AD; Uitermarkt B; Gander P; Howard M; Sternberg EJ; Nieto-Castanon A; Anteraper S; Whitfield-Gabrieli S; Brown EN; Boyden ES; Dickerson BC; Tsai LH
    PLoS One; 2022; 17(12):e0278412. PubMed ID: 36454969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Kv3.1/Kv3.2 promotes gamma oscillations by rescuing Aβ-induced desynchronization of fast-spiking interneuron firing in an AD mouse model in vitro.
    Andrade-Talavera Y; Arroyo-García LE; Chen G; Johansson J; Fisahn A
    J Physiol; 2020 Sep; 598(17):3711-3725. PubMed ID: 32638407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the use of gamma (multi)sensory stimulation for Alzheimer's disease treatment.
    Manippa V; Palmisano A; Filardi M; Vilella D; Nitsche MA; Rivolta D; Logroscino G
    Front Aging Neurosci; 2022; 14():1095081. PubMed ID: 36589536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gamma Oscillations in Alzheimer's Disease and Their Potential Therapeutic Role.
    Traikapi A; Konstantinou N
    Front Syst Neurosci; 2021; 15():782399. PubMed ID: 34966263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synchronization of β and γ oscillations in the somatosensory evoked neuromagnetic steady-state response.
    Ross B; Jamali S; Miyazaki T; Fujioka T
    Exp Neurol; 2013 Jul; 245():40-51. PubMed ID: 22955055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive auditory brain stimulation for gamma-band entrainment in dementia patients: An EEG dataset.
    Lahijanian M; Sedghizadeh MJ; Aghajan H; Vahabi Z
    Data Brief; 2022 Apr; 41():107839. PubMed ID: 35128001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.
    Koh SH; Kwon HS; Choi SH; Jeong JH; Na HR; Lee CN; Yang Y; Lee AY; Lee JH; Park KW; Han HJ; Kim BC; Park JS; Lee JY; Kim S; Lee KY
    Alzheimers Res Ther; 2021 Mar; 13(1):66. PubMed ID: 33771205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease.
    He Q; Colon-Motas KM; Pybus AF; Piendel L; Seppa JK; Walker ML; Manzanares CM; Qiu D; Miocinovic S; Wood LB; Levey AI; Lah JJ; Singer AC
    Alzheimers Dement (N Y); 2021; 7(1):e12178. PubMed ID: 34027028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on the effect of 40 Hz non-invasive light therapy system. A protocol for a randomized, double-blinded, placebo-controlled clinical trial.
    Agger MP; Horning M; Carstensen MS; Danielsen ER; Baandrup AO; Nguyen M; Høgh P; Miskowiak K; Petersen PM; Madsen KH; Kjær TW
    Front Aging Neurosci; 2023; 15():1250626. PubMed ID: 37901795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer's disease.
    Zhang F; Qin Y; Xie L; Zheng C; Huang X; Zhang M
    J Neural Transm (Vienna); 2019 Aug; 126(8):1081-1094. PubMed ID: 31292734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.